Mirabella Financial Services LLP Sells 26,875 Shares of Stryker Co. (NYSE:SYK)

Mirabella Financial Services LLP lessened its stake in shares of Stryker Co. (NYSE:SYK) by 82.2% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 5,825 shares of the medical technology company’s stock after selling 26,875 shares during the quarter. Mirabella Financial Services LLP’s holdings in Stryker were worth $2,096,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Morse Asset Management Inc boosted its holdings in Stryker by 16.5% during the 3rd quarter. Morse Asset Management Inc now owns 1,410 shares of the medical technology company’s stock valued at $509,000 after acquiring an additional 200 shares during the period. World Investment Advisors LLC grew its holdings in shares of Stryker by 126.1% in the third quarter. World Investment Advisors LLC now owns 8,142 shares of the medical technology company’s stock worth $2,941,000 after purchasing an additional 4,541 shares during the last quarter. Arvest Bank Trust Division purchased a new position in shares of Stryker in the third quarter worth $245,000. Wilmington Savings Fund Society FSB boosted its position in Stryker by 13.6% during the 3rd quarter. Wilmington Savings Fund Society FSB now owns 44,795 shares of the medical technology company’s stock valued at $16,183,000 after buying an additional 5,361 shares during the period. Finally, Tidal Investments LLC grew its holdings in Stryker by 13.9% in the 3rd quarter. Tidal Investments LLC now owns 17,478 shares of the medical technology company’s stock worth $6,314,000 after acquiring an additional 2,139 shares during the last quarter. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Stryker Stock Performance

Shares of NYSE SYK opened at $346.46 on Friday. The firm’s fifty day moving average is $370.95 and its two-hundred day moving average is $373.16. Stryker Co. has a 52-week low of $314.93 and a 52-week high of $406.19. The company has a market cap of $132.24 billion, a P/E ratio of 44.65, a P/E/G ratio of 2.93 and a beta of 0.93. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.32 and a current ratio of 1.95.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, beating analysts’ consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same quarter last year, the firm earned $3.46 earnings per share. As a group, analysts anticipate that Stryker Co. will post 13.47 EPS for the current fiscal year.

Stryker Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be issued a $0.84 dividend. The ex-dividend date of this dividend is Monday, March 31st. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.97%. Stryker’s dividend payout ratio (DPR) is presently 43.30%.

Analysts Set New Price Targets

SYK has been the subject of a number of research reports. Canaccord Genuity Group increased their price target on shares of Stryker from $420.00 to $435.00 and gave the stock a “buy” rating in a research note on Wednesday, January 29th. Argus set a $450.00 price target on Stryker in a research report on Monday, February 3rd. BTIG Research set a $403.00 price target on shares of Stryker and gave the company a “buy” rating in a report on Monday, April 14th. StockNews.com downgraded Stryker from a “buy” rating to a “hold” rating in a research note on Thursday, March 6th. Finally, JPMorgan Chase & Co. upped their price target on Stryker from $420.00 to $445.00 and gave the company an “overweight” rating in a report on Wednesday, January 29th. Five analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $423.53.

Insider Activity at Stryker

In other Stryker news, Director Allan C. Golston sold 2,458 shares of the business’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total transaction of $941,586.06. Following the transaction, the director now owns 14,895 shares in the company, valued at $5,705,827.65. The trade was a 14.16 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Ronda E. Stryker sold 201,392 shares of Stryker stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the transaction, the director now directly owns 3,642,075 shares of the company’s stock, valued at approximately $1,428,567,498. This represents a 5.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.90% of the stock is owned by insiders.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.